Company profile for Avidicure

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Avidicure is a Dutch biotech company developing AVC-Boosters, a novel class of dual agonistic, avidity-engineered antibodies designed to deliver potent and targeted monotherapy in oncology. These multifunctional molecules uniquely engage both innate and adaptive immunity, generating stronger and more coordinated immune responses than traditional therapies like checkpoint inhibitors or T-cell engagers. Supported by leading inve...
Avidicure is a Dutch biotech company developing AVC-Boosters, a novel class of dual agonistic, avidity-engineered antibodies designed to deliver potent and targeted monotherapy in oncology. These multifunctional molecules uniquely engage both innate and adaptive immunity, generating stronger and more coordinated immune responses than traditional therapies like checkpoint inhibitors or T-cell engagers. Supported by leading investors including EQT Life Sciences and BioGeneration Ventures, Avidicure is advancing this next-generation antibody platform to overcome limitations of current cancer immunotherapies.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Netherlands
Address
Address
De Limes 7 2342 DH Oegstgeest
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/05/22/3087159/0/en/Avidicure-to-Present-Preclinical-Data-from-Lead-TROP2-targeting-Multifunctional-Antibody-Program-at-the-2025-American-Society-of-Clinical-Oncology-Annual-Meeting.html

GLOBENEWSWIRE
22 May 2025

https://www.globenewswire.com/news-release/2025/04/24/3067295/0/en/Avidicure-Launches-with-50-Million-in-Seed-Financing-to-Develop-New-Multifunctional-Antibody-Modality-to-Treat-Cancer.html

GLOBENEWSWIRE
24 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty